BG
TBPH icon

Bellevue Group’s Theravance Biopharma TBPH Stock Holding History

Bellevue Group’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-10,628
Closed -$296K – 133
2017
Q4 		$296K Sell
10,628
-3,800
-26% -$112K 0.03% 134
2017
Q3 		$494K Hold
14,428
– – 0.05% 123
2017
Q2 		$575K Hold
14,428
– – 0.07% 123
2017
Q1 		$531K Sell
14,428
-1,000
-6% -$31.9K 0.07% 121
2016
Q4 		$492K Sell
15,428
-3,000
-16% -$93.1K 0.1% 112
2016
Q3 		$668K Buy
18,428
+7,000
+61% +$195K 0.12% 110
2016
Q2 		$259K Buy
11,428
+180
+2% +$3.89K 0.05% 118
2016
Q1 		$215K Buy
+11,248
New +$184K 0.04% 121

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bellevue Group's TBPH Position: Q1 2018 in Review

Bellevue Group sold out of Theravance Biopharma (TBPH) in Q1 2018, closing a stake of 10,628 shares — an estimated $296K sold.

Bellevue Group first reported a position in TBPH in Q1 2016 and held it in 8 quarters. The position peaked at $668K in Q3 2016. 90 funds tracked by Wall St. Rank hold TBPH as of Q1 2018.

  • Bellevue Group reported no remaining Theravance Biopharma position as of Q1 2018 after selling out during the quarter.
  • Bellevue Group sold 10,628 Theravance Biopharma shares in Q1 2018, an estimated $296K.
  • Bellevue Group first reported a position in Theravance Biopharma in Q1 2016 and held it in 8 quarters.
  • Bellevue Group's Theravance Biopharma position peaked at $668K in Q3 2016.
  • 90 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2018.

Based on Bellevue Group's 13F filing for Q1 2018, filed 9 May 2018.